Stakeholder outcome prioritization in the Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JS']JSpA) trial

被引:1
|
作者
Neu, Emily [1 ,2 ]
Sears, Cora [1 ,2 ]
Brandon, Timothy [1 ,2 ]
Kohlheim, Melanie [3 ]
Leal, Jenny [3 ]
Archie, Kweli [3 ]
Holland, English [3 ]
Holland, Miles [3 ]
Hameed, Aamena [3 ]
Khan, Asad [3 ]
Murphy, Lynn [3 ]
Murphy, Sean [3 ]
Neu, Antoinette [3 ]
Neu, Jerome [3 ]
Neu, Justin [3 ]
Richmond, Rachel [3 ]
Suplee, Dylan [3 ]
Suplee, Theresa [3 ]
Forrest, Christopher B. [3 ]
Weiss, Pamela F. [1 ,2 ,4 ,5 ]
机构
[1] Childrens Hosp Philadelphia, Clin Futures, Dept Pediat, Philadelphia, PA USA
[2] Childrens Hosp Philadelphia, A CHOP Res Inst, Ctr Emphasis, Philadelphia, PA USA
[3] Childrens Hosp Philadelphia, BACK OFF, JSpA Res Partners Grp, Philadelphia, PA USA
[4] Univ Penn, Perelman Sch Med, Dept Pediat & Epidemiol, Philadelphia, PA USA
[5] Childrens Hosp Philadelphia, Roberts Ctr Pediat Res, 2716 South St,Room 11121, Philadelphia, PA 19104 USA
关键词
patient-reported outcomes; spondyloarthritis; stakeholder; trial; tumour necrosis factor inhibitors; PATIENT-REPORTED OUTCOMES; PEDIATRIC-PATIENTS; CHILDREN;
D O I
10.1111/hex.13655
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA) study is a randomized, pragmatic trial investigating different tumour necrosis factor inhibitor de-escalation strategies for children with sustained inactive disease. In this project, we elicited concept rankings that aided in the selection of the patient-reported outcome (PRO) measures that should be examined as part of the BACK-OFF JSpA trial. Methods: We conducted a discrete choice experiment to evaluate individuals' preferences regarding PROs. Stakeholders assessed a discrete list of 21 outcome concepts, each of which had a Patient-Reported Outcome Measurement Information System (PROMIS) measure associated with it. PROMIS measures are self- or proxy-reported instruments that are universally applicable to the general population and all chronic conditions. Stakeholders were required to make choices instead of expressing the strength of a preference. Results: Fourteen caregivers, 12 patients (9-22 years old), 16 rheumatologists and three executives from health insurance companies completed the exercise, which took approximately 10 min. The discrete choice experiment resulted in an estimate of the relative importance of each outcome and rank. All stakeholder groups agreed that the primary PRO should be 'Pain Interference', a measure that evaluates the effect of pain on a child's everyday activities, including its impact on social, emotional, mental and physical functioning. Patients and caregivers were mostly aligned in their top priorities, with patients valuing physical health (50% of the top 10) whereas caregivers were more interested in mental health (60% of the top 10). Rheumatologists and health insurance executives were most interested in physical health outcomes, which were ranked 80% and 60% of their top 10 PROs, respectively. Overall, the patients had the most diverse set of prioritized outcomes, including at least one of each category in their top 10 rank order of importance. Patients were also the only stakeholders to prioritize 'social' health. Conclusions: Patients and caregivers were mostly aligned in their outcome priority rankings. The rank-order list directly informed the creation of a profile of PRO measures for our upcoming trial. Patient or Public Contribution: Stakeholder partners helped with acquisition of data and lead parent partners helped interpret data.
引用
收藏
页码:290 / 296
页数:7
相关论文
共 4 条
  • [1] Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JS']JSpA): study protocol for a randomized pragmatic trial
    Weiss, Pamela F. F.
    Sears, Cora E. E.
    Brandon, Timothy G. G.
    Forrest, Christopher B. B.
    Neu, Emily
    Kohlheim, Melanie
    Leal, Jenny
    Xiao, Rui
    Lovell, Daniel
    TRIALS, 2023, 24 (01)
  • [2] Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial
    Weiss, Pamela
    Sears, Cora
    Brandon, Timothy
    Xiao, Rui
    Aquino, Tory
    Archie, Kweli
    Hameed, Aamena
    Holland, English
    Holland, Miles
    Khan, Asad
    Kohlheim, Melanie
    Leal, Jennifer
    Murphy, Lynn
    Murphy, Sean
    Neu, Antoinette
    Neu, Emily
    Neu, Jerome
    Neu, Justin
    Richmond, Rachel
    Suplee, Theresa
    Suplee, Dylan
    Forrest, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3699 - 3701
  • [3] Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial
    Pamela F. Weiss
    Cora E. Sears
    Timothy G. Brandon
    Christopher B. Forrest
    Emily Neu
    Melanie Kohlheim
    Jenny Leal
    Rui Xiao
    Daniel Lovell
    Trials, 24
  • [4] Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
    Sears, Cora
    Muir, Cassandra
    Brandon, Timothy
    Ferguson, Polly
    Correll, Colleen
    Rosenkranz, Margalit
    Baszis, Kevin
    Lee, Tzielan
    Oberle, Edward
    Stoll, Matthew
    Cook, Kathryn
    Muscal, Eyal
    Srinivasalu, Hemalatha
    Lovell, Daniel
    Prahalad, Sampath
    Cidon, Michal
    Mulvihill, Evan
    Klein-Gitelman, Marisa
    Kingsbury, Daniel
    Cooper, Jennifer
    Rosenwasser, Natalie
    Treemarcki, Erin
    Chang, Joyce
    Tarvin, Stacey
    Walters, Heather
    Shishov, Michael
    Buckley, Lisa
    Toth, Mary
    Cooper, Ashley
    Xiao, Rui
    Neu, Emily
    Kohlheim, Melanie
    Leal, Jenny
    Archie, Kweli
    Holland, English
    Holland, Miles
    Hameed, Aamena
    Khan, Asad
    Murphy, Lynn
    Murphy, Sean
    Neu, Justin
    Richmond, Rachel
    Suplee, Dylan
    Suplee, Theresa
    Wiley, Dawn
    Weiss, Pamela
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 797 - 800